Portfolio Holdings Detail for ISIN IE00BDZVHG35
| Stock Name / Fund | iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) |
| Issuer | Blackrock |
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 67
| ETF Ticker | BTEE(USD) LSE |
| ETF Ticker | BTEE.L(GBP) LSE |
Holdings detail for SNY
| Stock Name | Sanofi ADR |
| Ticker | SNY(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US80105N1054 |
| LEI | 549300E9PC51EN656011 |
Show aggregate SNY holdings
News associated with SNY
- Regeneron And Sanofi : CHMP Recommends EU Approval Of Dupixent For Chronic Spontaneous Urticaria
- (RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi announced that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion recommending the approval of Dupixent (dupilumab) in the European Union for treating c - 2025-09-22 02:12:20
- Sanofi (NASDAQ:SNY) Shares Acquired Rep. Lisa C. McClain
- Representative Lisa C. McClain (R-Michigan) recently bought shares of Sanofi (NASDAQ:SNY). In a filing disclosed on September 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Sanofi stock on August 4th. The trade occurred in the Representative’s “CHARLES SCHWAB BROKERAGE ACCOUNT 924” account. Representative Lisa C. McClain also recently made the […] - 2025-09-17 03:08:42
- Sanofi's Brivekimig Shows Efficacy In Biologic-Naïve HS Patients In Phase 2a Study
- (RTTNews) - Sanofi (SNY) announced promising new data from its HS-OBTAIN phase 2a study, highlighting the efficacy of brivekimig in treating biologic-naïve patients with moderate-to-severe hidradenitis suppurativa (HS). - 2025-09-17 02:33:17
- Sanofi: FDA Grants Fast Track Designation For SAR402663
- (RTTNews) - Sanofi said the FDA has granted fast track designation to SAR402663, an investigational one-time intravitreal gene therapy for the treatment of neovascular age-related macular degeneration. Sanofi is currently evaluating SAR402663 in a phase 1/2 for the treatment of p - 2025-09-11 02:36:46
- Morgan Stanley Upgrades Sanofi (NASDAQ:SNY) to “Overweight”
- Sanofi (NASDAQ:SNY – Get Free Report) was upgraded by Morgan Stanley from an “equal weight” rating to an “overweight” rating in a research note issued on Monday, Marketbeat.com reports. The firm currently has a $58.00 target price on the stock, up from their previous target price of $56.00. Morgan Stanley’s target price suggests a potential […] - 2025-09-10 03:00:55
- Why Nektar Therapeutics Rippled Higher This Week
- Key PointsInvestors are pricing in a better commercial outcome for a drug that isn't even in phase 3 yet. - 2025-09-05 14:32:33
- Sanofi's Amlitelimab Meets Primary & Key Secondary Endpoints In Phase 3 Study For Atopic Dermatitis
- (RTTNews) - Sanofi SA's (SAN.PA, SNYNF, SNY) investigational therapy, amlitelimab, has achieved a significant milestone in the COAST 1 phase 3 clinical trial, meeting all primary and key secondary endpoints in adults and adolescents with moderate-to-severe atopic dermatitis. Admi - 2025-09-04 02:27:43
- Implied PID Analyst Target Price: $23
- Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-09-03 08:00:10
- Mitsubishi UFJ Asset Management Co. Ltd. Acquires 253 Shares of Sanofi (NASDAQ:SNY)
- Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in Sanofi (NASDAQ:SNY – Free Report) by 6.7% in the 1st quarter, HoldingsChannel reports. The firm owned 4,032 shares of the company’s stock after buying an additional 253 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Sanofi were worth $224,000 as of […] - 2025-08-15 04:47:04
- Atria Wealth Solutions Inc. Sells 1,794 Shares of Sanofi (NASDAQ:SNY)
- Atria Wealth Solutions Inc. decreased its position in shares of Sanofi (NASDAQ:SNY – Free Report) by 10.2% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 15,855 shares of the company’s stock after selling 1,794 shares during the quarter. Atria Wealth Solutions Inc.’s holdings […] - 2025-08-12 05:09:02
- Sanofi (NASDAQ:SNY) Rating Increased to Buy at Wall Street Zen
- Wall Street Zen upgraded shares of Sanofi (NASDAQ:SNY – Free Report) from a hold rating to a buy rating in a report published on Saturday morning. Other research analysts have also issued reports about the company. Morgan Stanley set a $56.00 target price on Sanofi in a research report on Monday, June 2nd. Barclays reaffirmed […] - 2025-08-05 02:56:56
- Analyzing Sanofi (NASDAQ:SNY) and Roche (OTCMKTS:RHHBY)
- Sanofi (NASDAQ:SNY – Get Free Report) and Roche (OTCMKTS:RHHBY – Get Free Report) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, valuation, analyst recommendations and institutional ownership. Valuation & Earnings This table compares Sanofi and Roche”s […] - 2025-08-04 04:30:52
- The Math Shows FVD Can Go To $50
- Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-07-31 09:19:44
- Sanofi (NASDAQ:SNY) versus Roche (OTCMKTS:RHHBY) Critical Comparison
- Sanofi (NASDAQ:SNY – Get Free Report) and Roche (OTCMKTS:RHHBY – Get Free Report) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, analyst recommendations and institutional ownership. Insider and Institutional Ownership 14.0% of Sanofi shares are […] - 2025-07-30 03:02:41
- The Median Retirement Savings for American Households Is $87,000. Here Are 3 Incredible Stocks to Buy Now and Hold for Decades.
- Key PointsArtificial intelligence-powered drug development isn't a mere premise anymore. Recursion Pharmaceuticals has made it a reality. - 2025-07-26 19:14:00
- Sanofi's Sarclisa Combination Gets EU Approval For Treating Newly Diagnosed Multiple Myeloma
- (RTTNews) - Sanofi Winthrop Industrie said that the European Commission has approved Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for the induction treatment of adult patients with newly diagnosed multiple myeloma (NDMM) who are eligible for auto - 2025-07-25 02:16:12
- Sanofi (NASDAQ:SNY) Shares Sold by Choreo LLC
- Choreo LLC lowered its position in shares of Sanofi (NASDAQ:SNY – Free Report) by 21.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 45,889 shares of the company’s stock after selling 12,555 shares during the period. Choreo LLC’s holdings in Sanofi were worth […] - 2025-07-24 08:28:55
- Sanofi's SAR446597 Granted FDA Fast Track For Gene Therapy Tackling Vision Loss In AMD
- (RTTNews) - Sanofi S.A. (SNYNF,SNY) said that the U.S. Food and Drug Administration has granted fast track designation to SAR446597, a one-time intravitreal gene therapy for the treatment of geographic atrophy (GA) due to age-related macular degeneration or AMD. - 2025-07-16 02:29:02
- Cerity Partners LLC Has $10.91 Million Holdings in Sanofi (NASDAQ:SNY)
- Cerity Partners LLC increased its stake in shares of Sanofi (NASDAQ:SNY – Free Report) by 62.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 196,726 shares of the company’s stock after buying an additional 75,698 shares during the quarter. Cerity Partners LLC’s […] - 2025-07-15 08:30:17
- Concurrent Investment Advisors LLC Decreases Stock Holdings in Sanofi (NASDAQ:SNY)
- Concurrent Investment Advisors LLC trimmed its position in shares of Sanofi (NASDAQ:SNY – Free Report) by 74.4% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 9,700 shares of the company’s stock after selling 28,246 shares during the quarter. Concurrent Investment Advisors LLC’s holdings in […] - 2025-07-11 05:50:49
- Bank of New York Mellon Corp Sells 840,093 Shares of Sanofi (NASDAQ:SNY)
- Bank of New York Mellon Corp lowered its position in Sanofi (NASDAQ:SNY – Free Report) by 30.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,945,223 shares of the company’s stock after selling 840,093 shares during the quarter. Bank of New York […] - 2025-07-10 05:35:08
- Leerink Partnrs Estimates Sanofi’s Q2 Earnings (NASDAQ:SNY)
- Sanofi (NASDAQ:SNY – Free Report) – Stock analysts at Leerink Partnrs cut their Q2 2025 earnings per share (EPS) estimates for Sanofi in a research report issued to clients and investors on Monday, July 7th. Leerink Partnrs analyst D. Risinger now expects that the company will post earnings per share of $0.94 for the quarter, […] - 2025-07-10 02:17:01
- Financial Review: Sanofi (NASDAQ:SNY) & Merck & Co., Inc. (NYSE:MRK)
- Sanofi (NASDAQ:SNY – Get Free Report) and Merck & Co., Inc. (NYSE:MRK – Get Free Report) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings and dividends. Insider and Institutional Ownership 14.0% of […] - 2025-07-09 05:36:55
- Leerink Partnrs Predicts Sanofi’s Q3 Earnings (NASDAQ:SNY)
- Sanofi (NASDAQ:SNY – Free Report) – Research analysts at Leerink Partnrs raised their Q3 2025 EPS estimates for Sanofi in a report issued on Monday, July 7th. Leerink Partnrs analyst D. Risinger now forecasts that the company will post earnings of $1.77 per share for the quarter, up from their previous estimate of $1.76. The […] - 2025-07-09 02:10:51
- Private Trust Co. NA Purchases 697 Shares of Sanofi (NASDAQ:SNY)
- Private Trust Co. NA raised its position in Sanofi (NASDAQ:SNY – Free Report) by 19.8% in the 1st quarter, Holdings Channel reports. The firm owned 4,220 shares of the company’s stock after buying an additional 697 shares during the quarter. Private Trust Co. NA’s holdings in Sanofi were worth $234,000 at the end of the […] - 2025-07-08 04:52:56
- Analysts Set Sanofi (NASDAQ:SNY) Price Target at $61.50
- Sanofi (NASDAQ:SNY – Get Free Report) has been assigned an average rating of “Buy” from the eight ratings firms that are currently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, three have given a buy rating and three have assigned a strong buy rating to […] - 2025-07-02 02:22:53
- Sanofi (NASDAQ:SNY) Shares Sold by Transcend Capital Advisors LLC
- Transcend Capital Advisors LLC lowered its stake in shares of Sanofi (NASDAQ:SNY – Free Report) by 30.7% in the first quarter, HoldingsChannel reports. The fund owned 3,895 shares of the company’s stock after selling 1,728 shares during the quarter. Transcend Capital Advisors LLC’s holdings in Sanofi were worth $216,000 at the end of the most […] - 2025-07-01 05:26:59
- Sequoia Financial Advisors LLC Increases Stake in Sanofi (NASDAQ:SNY)
- Sequoia Financial Advisors LLC increased its position in shares of Sanofi (NASDAQ:SNY – Free Report) by 15.6% during the 1st quarter, Holdings Channel reports. The institutional investor owned 24,272 shares of the company’s stock after purchasing an additional 3,269 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Sanofi were worth $1,346,000 at the […] - 2025-06-30 05:37:03
- Sanofi's Riliprubart Secures U.S. Orphan Drug Status For Solid Organ Transplant Rejection
- (RTTNews) - The U.S. Food and Drug Administration has granted orphan drug designation to riliprubart for the investigational treatment of antibody-mediated rejection (AMR) in solid organ transplantation, Sanofi Winthrop Industrie said in a statement. - 2025-06-25 02:39:22
- Sanofi's Sarclisa Recommended For EU Approval To Treat Transplant-eligible Newly Diagnosed MM
- (RTTNews) - French drug major Sanofi S.A. (SNYNF,SNY) announced Monday that Sarclisa (isatuximab) has been recommended for European Union approval by the Committee for Medicinal Products for Human Use or CHMP to treat transplant-eligible newly diagnosed multiple myeloma, based on - 2025-06-23 02:53:56
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) SNY holdings
| Date | Number of SNY Shares Held | Base Market Value of SNY Shares | Local Market Value of SNY Shares | Change in SNY Shares Held | Change in SNY Base Value | Current Price per SNY Share Held | Previous Price per SNY Share Held |
|---|
| 2026-02-09 (Monday) | 193,264 | USD 9,328,853 | USD 9,328,853 | | | | |
| 2026-02-06 (Friday) | 192,834 | USD 9,223,250 | USD 9,223,250 | 430 | USD 128,313 | USD 47.83 | USD 47.27 |
| 2026-02-02 (Monday) | 192,404 | USD 9,094,937 | USD 9,094,937 | 0 | USD 44,253 | USD 47.27 | USD 47.04 |
| 2026-01-30 (Friday) | 192,404 | USD 9,050,684 | USD 9,050,684 | 860 | USD 201,351 | USD 47.04 | USD 46.2 |
| 2026-01-29 (Thursday) | 191,544 | USD 8,849,333 | USD 8,849,333 | 430 | USD -226,671 | USD 46.2 | USD 47.49 |
| 2026-01-27 (Tuesday) | 191,114 | USD 9,076,004 | USD 9,076,004 | 430 | USD 50,930 | USD 47.49 | USD 47.33 |
| 2026-01-26 (Monday) | 190,684 | USD 9,025,074 | USD 9,025,074 | 0 | USD 24,789 | USD 47.33 | USD 47.2 |
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of SNY by Blackrock for IE00BDZVHG35
Show aggregate share trades of SNY| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2026-02-06 | BUY | 430 | | | 47.830* | | - |
| 2026-01-30 | BUY | 860 | 47.240 | 46.580 | 46.646 | USD 40,116 | - |
| 2026-01-29 | BUY | 430 | 46.400 | 45.790 | 45.851 | USD 19,716 | - |
| 2026-01-27 | BUY | 430 | 47.885 | 47.370 | 47.421 | USD 20,391 | - |
| 2026-01-23 | BUY | 860 | 47.250 | 46.095 | 46.211 | USD 39,741 | - |
| 2026-01-22 | BUY | 430 | 46.860 | 46.210 | 46.275 | USD 19,898 | - |
| 2026-01-16 | BUY | 7,954 | 47.030 | 46.490 | 46.544 | USD 370,211 | - |
| 2026-01-15 | BUY | 824 | 47.635 | 47.100 | 47.153 | USD 38,854 | - |
| 2026-01-14 | BUY | 824 | 48.160 | 47.750 | 47.791 | USD 39,380 | - |
| 2026-01-12 | BUY | 824 | 48.900 | 47.550 | 47.685 | USD 39,292 | - |
| 2026-01-09 | BUY | 1,236 | | | 49.030* | | - |
| 2026-01-07 | BUY | 824 | | | 48.370* | | - |
| 2026-01-02 | BUY | 412 | 48.480 | 48.148 | 48.182 | USD 19,851 | - |
| 2025-12-30 | BUY | 412 | 48.945 | 48.665 | 48.693 | USD 20,062 | - |
| 2025-12-23 | SELL | -4,944 | 48.737 | 48.220 | 48.272 | USD -238,655 | - |
| 2025-12-19 | SELL | -17,606 | 48.450 | 47.710 | 47.784 | USD -841,285 | - |
| 2025-12-17 | SELL | -2,260 | 48.410 | 47.600 | 47.681 | USD -107,759 | - |
| 2025-12-16 | SELL | -452 | 48.000 | 47.190 | 47.271 | USD -21,366 | - |
| 2025-12-15 | BUY | 904 | 48.605 | 46.970 | 47.134 | USD 42,609 | - |
| 2025-12-11 | BUY | 2,979 | 49.240 | 48.620 | 48.682 | USD 145,024 | - |
| 2025-12-04 | BUY | 8,940 | 49.570 | 48.890 | 48.958 | USD 437,685 | - |
| 2025-12-02 | BUY | 6,705 | 50.430 | 49.680 | 49.755 | USD 333,607 | - |
| 2025-11-28 | BUY | 447 | 49.930 | 49.620 | 49.651 | USD 22,194 | - |
| 2025-11-26 | BUY | 1,341 | 50.090 | 49.500 | 49.559 | USD 66,459 | - |
| 2025-11-25 | BUY | 2,235 | 50.610 | 49.250 | 49.386 | USD 110,378 | - |
| 2025-11-24 | BUY | 447 | 49.890 | 49.140 | 49.215 | USD 21,999 | - |
| 2025-11-20 | SELL | -1,788 | 49.930 | 48.730 | 48.850 | USD -87,344 | - |
| 2025-11-19 | BUY | 447 | 50.520 | 49.290 | 49.413 | USD 22,088 | - |
| 2025-11-18 | BUY | 2,682 | 50.940 | 50.480 | 50.526 | USD 135,511 | - |
| 2025-11-17 | BUY | 894 | 52.670 | 51.710 | 51.806 | USD 46,315 | - |
| 2025-11-14 | BUY | 447 | 52.430 | 52.000 | 52.043 | USD 23,263 | - |
| 2025-11-12 | BUY | 447 | 52.440 | 51.900 | 51.954 | USD 23,223 | - |
| 2025-11-10 | BUY | 445 | 50.680 | 49.980 | 50.050 | USD 22,272 | - |
| 2025-11-06 | BUY | 445 | 49.680 | 49.060 | 49.122 | USD 21,859 | - |
| 2025-11-04 | BUY | 447 | 49.800 | 48.670 | 48.783 | USD 21,806 | - |
| 2025-10-30 | BUY | 2,235 | 51.330 | 50.835 | 50.884 | USD 113,727 | - |
| 2025-10-29 | BUY | 1,602 | 50.680 | 51.635 | 51.539 | USD 82,566 | - |
| 2025-10-22 | SELL | -1,780 | 49.990 | 50.480 | 50.431 | USD -89,767 | - |
| 2025-10-20 | BUY | 890 | 49.730 | 50.510 | 50.432 | USD 44,884 | - |
| 2025-10-17 | BUY | 2,223 | 50.620 | 50.720 | 50.710 | USD 112,728 | - |
| 2025-10-15 | BUY | 3,544 | 48.960 | 49.160 | 49.140 | USD 174,152 | - |
| 2025-10-03 | BUY | 3,087 | 50.900 | 51.050 | 51.035 | USD 157,545 | - |
| 2025-10-02 | BUY | 441 | 50.140 | 50.350 | 50.329 | USD 22,195 | - |
| 2025-09-30 | BUY | 882 | 47.200 | 47.220 | 47.218 | USD 41,646 | - |
| 2025-09-26 | BUY | 882 | 45.540 | 45.840 | 45.810 | USD 40,404 | - |
| 2025-09-25 | BUY | 882 | 45.070 | 45.700 | 45.637 | USD 40,252 | - |
| 2025-09-18 | BUY | 484 | 47.680 | 48.000 | 47.968 | USD 23,217 | - |
| 2025-09-17 | BUY | 1,458 | 46.970 | 47.330 | 47.294 | USD 68,955 | - |
| 2025-07-17 | SELL | -972 | 48.650 | 48.650 | 48.650 | USD -47,288 | - |
| 2025-07-16 | BUY | 1,663 | 48.520 | 48.750 | 48.727 | USD 81,033 | - |
| 2025-07-11 | SELL | -3,848 | 48.610 | 48.750 | 48.736 | USD -187,536 | - |
| 2025-07-02 | BUY | 26,455 | 49.310 | 49.370 | 49.364 | USD 1,305,925 | - |
| 2025-06-25 | BUY | 962 | 47.800 | 48.150 | 48.115 | USD 46,287 | - |
| 2025-06-20 | BUY | 1,235 | 47.860 | 48.110 | 48.085 | USD 59,385 | - |
| 2025-06-11 | BUY | 954 | 49.700 | 50.060 | 50.024 | USD 47,723 | - |
| 2025-06-10 | BUY | 954 | 49.880 | 50.160 | 50.132 | USD 47,826 | - |
| 2025-06-04 | SELL | -477 | 49.500 | 49.770 | 49.743 | USD -23,727 | - |
| 2025-04-23 | BUY | 477 | 53.020 | 53.090 | 53.083 | USD 25,321 | - |
| 2025-04-10 | SELL | -3,816 | 49.660 | 50.210 | 50.155 | USD -191,391 | - |
| 2025-04-08 | SELL | -477 | 49.860 | 51.340 | 51.192 | USD -24,419 | - |
| 2025-04-07 | SELL | -477 | 50.760 | 52.190 | 52.047 | USD -24,826 | - |
| 2025-04-04 | SELL | -2,385 | 51.980 | 53.860 | 53.672 | USD -128,008 | - |
| 2025-04-01 | BUY | 3,830 | 54.340 | 55.500 | 55.384 | USD 212,121 | - |
| 2025-03-31 | SELL | -1,410 | 55.460 | 55.620 | 55.604 | USD -78,402 | - |
| 2025-03-14 | SELL | -7,536 | 57.750 | 57.930 | 57.912 | USD -436,425 | - |
| 2025-03-07 | SELL | -942 | 59.250 | 59.660 | 59.619 | USD -56,161 | - |
| 2025-03-04 | SELL | -471 | 57.700 | 57.840 | 57.826 | USD -27,236 | - |
| 2025-02-25 | BUY | 942 | 54.890 | 55.000 | 54.989 | USD 51,800 | - |
| 2025-02-19 | SELL | -471 | 53.600 | 53.750 | 53.735 | USD -25,309 | - |
| 2025-02-13 | BUY | 1,410 | 53.990 | 55.040 | 54.935 | USD 77,458 | - |
| 2025-02-12 | BUY | 470 | 54.560 | 54.870 | 54.839 | USD 25,774 | - |
| 2025-02-11 | BUY | 1,880 | 53.900 | 54.000 | 53.990 | USD 101,501 | - |
| 2024-12-30 | SELL | -12,501 | 48.230 | 48.650 | 48.608 | USD -607,649 | - |
| 2024-11-18 | SELL | -7,545 | 48.510 | 48.670 | 48.654 | USD -367,094 | - |
| 2024-11-08 | SELL | -503 | 51.320 | 51.620 | 51.590 | USD -25,950 | - |
| 2024-10-30 | BUY | 525 | 53.450 | 53.720 | 53.693 | USD 28,189 | - |
| 2024-10-21 | SELL | -501 | 53.660 | 54.650 | 54.551 | USD -27,330 | - |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of SNY
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-09-19 | 813,243 | 0 | 1,931,044 | 42.1% |
| 2025-09-18 | 441,657 | 0 | 990,364 | 44.6% |
| 2025-09-17 | 494,396 | 7,107 | 1,168,801 | 42.3% |
| 2025-09-16 | 370,565 | 1 | 805,100 | 46.0% |
| 2025-09-15 | 315,160 | 639 | 1,296,517 | 24.3% |
| 2025-09-12 | 674,665 | 112 | 1,437,852 | 46.9% |
| 2025-09-11 | 346,691 | 0 | 839,955 | 41.3% |
| 2025-09-10 | 386,771 | 893 | 733,777 | 52.7% |
| 2025-09-09 | 307,089 | 0 | 1,182,306 | 26.0% |
| 2025-09-08 | 354,047 | 28 | 1,638,243 | 21.6% |
| 2025-09-05 | 911,755 | 3,273 | 3,562,999 | 25.6% |
| 2025-09-04 | 1,219,250 | 7,859 | 3,695,065 | 33.0% |
| 2025-09-03 | 468,329 | 77 | 865,044 | 54.1% |
| 2025-09-02 | 776,649 | 1,349 | 1,006,020 | 77.2% |
| 2025-08-29 | 615,744 | 300 | 866,983 | 71.0% |
| 2025-08-28 | 249,394 | 2 | 648,159 | 38.5% |
| 2025-08-27 | 352,244 | 28 | 910,403 | 38.7% |
| 2025-08-26 | 283,779 | 333 | 585,674 | 48.5% |
| 2025-08-25 | 483,515 | 1,600 | 729,780 | 66.3% |
| 2025-08-22 | 376,931 | 100 | 719,515 | 52.4% |
| 2025-08-21 | 408,639 | 4,290 | 628,405 | 65.0% |
| 2025-08-20 | 432,605 | 36 | 656,749 | 65.9% |
| 2025-08-19 | 333,115 | 451 | 632,816 | 52.6% |
| 2025-08-18 | 636,082 | 5,491 | 1,330,260 | 47.8% |
| 2025-08-15 | 444,632 | 308 | 985,361 | 45.1% |
| 2025-08-14 | 450,207 | 731 | 1,543,051 | 29.2% |
| 2025-08-13 | 364,511 | 4 | 581,785 | 62.7% |
| 2025-08-12 | 375,681 | 1,200 | 586,215 | 64.1% |
| 2025-08-11 | 595,525 | 8,300 | 1,152,711 | 51.7% |
| 2025-08-08 | 659,929 | 2,400 | 1,312,511 | 50.3% |
| 2025-08-07 | 976,538 | 11 | 1,701,325 | 57.4% |
| 2025-08-06 | 1,016,498 | 4,522 | 1,527,433 | 66.5% |
| 2025-08-05 | 774,122 | 4,874 | 1,207,826 | 64.1% |
| 2025-08-04 | 672,333 | 1,553 | 1,193,407 | 56.3% |
| 2025-08-01 | 680,953 | 2,132 | 1,296,108 | 52.5% |
| 2025-07-31 | 1,876,446 | 2,175 | 4,218,175 | 44.5% |
| 2025-07-30 | 499,888 | 0 | 902,317 | 55.4% |
| 2025-07-29 | 987,986 | 0 | 1,653,496 | 59.8% |
| 2025-07-28 | 350,742 | 0 | 964,845 | 36.4% |
| 2025-07-25 | 190,589 | 84 | 681,542 | 28.0% |
| 2025-07-24 | 242,334 | 2 | 726,582 | 33.4% |
| 2025-07-23 | 367,937 | 243 | 877,773 | 41.9% |
| 2025-07-22 | 228,781 | 267 | 509,409 | 44.9% |
| 2025-07-21 | 241,723 | 0 | 634,807 | 38.1% |
| 2025-07-18 | 229,451 | 900 | 578,320 | 39.7% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Note: All information is provided as is without warranty and should be used for indicative purposes only.
You should independently check data before making any investment decision.
This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.
Copyright Market Footprint Ltd. Privacy Policy